Publications by authors named "M D Hogarty"
Article Synopsis
- Tumor invasion of the spinal canal occurs in about 15% of newly diagnosed neuroblastoma patients, prompting a need for effective treatment strategies that optimize survival while minimizing long-term effects.
- A study of 92 intermediate-risk neuroblastoma patients with intraspinal tumors revealed that nearly half were symptomatic at diagnosis, but most of them experienced complete resolution of symptoms following treatment, regardless of the initial severity or duration of their deficits.
- The findings suggest that while prompt diagnosis and chemotherapy are crucial, surgical options like laminectomy may not significantly improve motor symptoms, indicating that surgery should be reserved for cases with rapid worsening neurologic conditions.
Background: The International Neuroblastoma Risk Group (INRG) classifier utilizes a staging system based on pretreatment imaging criteria in which image-defined risk factors (IDRFs) are used to evaluate the extent of locoregional disease. Children's Oncology Group (COG) study ANBL0531 prospectively examined institutional determination of IDRF status and compared that to a standardized central review.
Methods: Between 9/2009-6/2011, patients with intermediate-risk neuroblastoma were enrolled on ANBL0531 and had IDRF assessment at treating institutions.
Unlabelled: Broadly neutralizing antibodies targeting the V2 apex of the HIV-1 envelope trimer are among the most common specificities elicited in HIV-1-infected humans and simian-human immunodeficiency virus (SHIV)-infected macaques. To gain insight into the prevalent induction of these antibodies, we isolated and characterized 11 V2 apex-directed neutralizing antibody lineages from SHIV-infected rhesus macaques. Remarkably, all SHIV-induced V2 apex lineages were derived from reading frame two of the rhesus DH3-15*01 gene.
View Article and Find Full Text PDFLangerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by lesions with CD1a-positive/Langerin (CD207)-positive histiocytes and inflammatory infiltrate that can cause local tissue damage and systemic inflammation. Clinical presentations range from single lesions with minimal impact to life-threatening disseminated disease. Therapy for systemic LCH has been established through serial trials empirically testing different chemotherapy agents and durations of therapy.
View Article and Find Full Text PDF